Consensus Liquidia Corporation

Equities

LQDA

US53635D2027

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
12.5 ^USD	-2.65%		-5.09%	+3.91%

04-01	Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	MT
04-01	Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	DJ

Evolution of the average Target Price on Liquidia Corporation

Price target over the last 5 years

History of analyst recommendation changes

32be.I_1zcmEqCzBgo5EYo3f9WSHtGrEEFDm06sLTLlVyFFQ.ZLowJANiRXc1-dh0wgelDmKEU-htOXHsk52VRQEmJxlBkhkbUWtpZzbK1A~cb125d861b498b73ea3a2a6c29f2cb07

Analyst Recommendations on Liquidia Corporation

Liquidia Insider Sold Shares Worth $452,183, According to a Recent SEC Filing	03-20	MT
HC Wainwright Adjusts Price Target on Liquidia to $32 From $16, Maintains Buy Rating	03-14	MT
BofA Securities Raises Price Target on Liquidia to $15 From $13, Maintains Buy Rating	12-21	MT
Needham Adjusts Price Target on Liquidia to $18 From $16, Maintains Buy Rating	17/03/23	MT
Needham Raises Liquidia's Price Target to $16 From $12, Maintains Buy Rating	01/09/22	MT
Wedbush Lowers Liquidia to Underperform From Neutral, Price Target to $3 From $4 on Adjusted Yutrepia Timeline	01/09/22	MT
Ladenburg Thalmann Initiates Coverage of Liquidia at Buy with $15 Price Target	22/07/22	MT
BTIG Adjusts Liquidia's Price Target to $17 From $14, Reiterates Buy Rating	20/07/22	MT
BTIG Starts Liquidia at Buy With $14 Price Target	31/05/22	MT
BofA Securities Starts Liquidia at Buy With $12 Price Target	26/05/22	MT
Wedbush Cuts Price Target on Liquidia Technologies to $4 From $6, Following Tyvaso Regulatory Update, Maintains Neutral Rating	24/05/22	MT
Wedbush Cuts Price Target on Liquidia Technologies to $4 From $6, Citing Tyvaso Market Penetration Estimates, Maintains Neutral Rating	24/05/22	MT
HC Wainwright Adjusts Liquidia Technologies' Price Target to $16 From $6, Keeps Buy Rating	03/02/22	MT
Needham Adjusts Liquidia Technologies' Price Target to $12 from $8, Keeps Buy Rating	10/01/22	MT
Wedbush Lifts Liquidia Technologies' Price Target to $6 From $2; Neutral Rating Kept	09/11/21	MT
LIQUIDIA : Wedbush Adjusts Price Target for Liquidia Technologies to $2 From $3, Maintains Neutral Rating	13/05/21	MT
LIQUIDIA : Wedbush Adjusts Liquidia Technologies' PT to $3 From $2, Citing Subcutaneous Treprostinil for Pulmonary Arterial Hypertension; Neutral Rating Kept	31/03/21	MT
LIQUIDIA : Wedbush Adjusts Price Target on Liquidia Technologies to $2 From $4 on Lowered LIQ861/PAH Penetration Rate Estimates; Neutral Rating Kept	30/03/21	MT
LIQUIDIA : HC Wainwright Initiates Liquidia Technologies at Buy With $6 Price Target	04/12/20	MT
LIQUIDIA : Wedbush Cuts Liquidia Technologies to Neutral From Outperform on LIQ861 Regulatory Headwind, LIQ865 US Launch Timeline; PT to $4 From $20	20/11/20	MT